Amoxicillin, Clarithromycin — Competitive Intelligence Brief

Amoxicillin, Clarithromycin (Amoxicillin, Clarithromycin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic and macrolide antibiotic combination. Area: Infectious Disease.

marketed Beta-lactam antibiotic and macrolide antibiotic combination Bacterial cell wall (amoxicillin); bacterial 50S ribosome (clarithromycin) Infectious Disease Small molecule

Target snapshot

Amoxicillin, Clarithromycin (Amoxicillin, Clarithromycin) — Mackay Memorial Hospital. Amoxicillin and clarithromycin are antibiotics that work together to inhibit bacterial protein synthesis and cell wall formation, commonly used in combination therapy for H. pylori eradication.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amoxicillin, Clarithromycin TARGET	Amoxicillin, Clarithromycin	Mackay Memorial Hospital	marketed	Beta-lactam antibiotic and macrolide antibiotic combination	Bacterial cell wall (amoxicillin); bacterial 50S ribosome (clarithromycin)
ceftriaxone and azithromycin	ceftriaxone and azithromycin	Sheba Medical Center	marketed	Beta-lactam antibiotic and macrolide antibiotic combination	Bacterial cell wall (ceftriaxone) and bacterial 50S ribosome (azithromycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic and macrolide antibiotic combination class)

1. Mackay Memorial Hospital · 1 drug in this class
2. Sheba Medical Center · 1 drug in this class